Login to Your Account



Viread successor TAF wins FDA nod in HBV

By Jennifer Boggs
Managing Editor

Thursday, November 10, 2016

Gilead Sciences Inc.'s Vemlidy – better known as tenofovir alafenamide, or TAF – won FDA approval as expected for treating adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription